A few days back, Bangladesh has postponed a special drive due to a shortage of COVID-19 vaccines. A successful human trial for this new vaccine would reduce dependency on syringes, reduce the hassle of maintaining a cold chain.
This would be a great opportunity for Bangladesh to produce COVID 19 vaccines locally by securing demand for vaccination.
According to ISR scientists, the dry-powder vaccine uses manufactured Covid-19 virus proteins and can withstand temperature of up to 40 degrees Celsius. They also said a major advantage of the vaccine in development is the conditions needed to store it compared to the currently available Covid vaccines approved by the World Health Organization. "The game-changer is that you could distribute the [powder] vaccine extremely easily without the cold chain, and it can be administered without the need for healthcare providers," said a BBC report on July 26 quoting ISR founder, Ola Winquist, a professor of immunology at the Karolinska Institute, one of Sweden's leading medical universities.
unknownx500
